BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

BioStock: PHI charts a bold course to impact regenerative medicine

BioStock: PHI charts a bold course to impact regenerative medicine

BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.
righst issue of units 2022 banner

BioStock: The five best life science stocks of the first half-year

PHI is proud to be highlighted as one of the top 5 best-performing Swedish life science stocks in the first half of 2023.
PHI-worldtour-1024x576

BioStock: PHI’s CEO reflects on global roadshow success

BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.
Biostock-PHI-on-how-TO-3-proceeds-will-be-used

BioStock: PHI on how TO 3 proceeds will be used

BioStock talked to CEO Patrik Eschricht to learn how the TO 3 proceeds would be used.
123456…8

Latest News

PHI-accelerates-growth-with-record-order-biostock

BioStock: PHI accelerates growth with record order

PHI recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)

The shareholders of Phase Holographic Imaging PHI AB (publ), reg. nr. 556542-7811, are hereby invited to attend the annual general meeting on the 31 October 2024 at 11.00 at the company´s office at Skiffervägen 48 in Lund.

The last day of trading in warrants of series TO 4 is on 1 October 2024

The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s preferential rights issue of units that was carried out in 2022. The exercise period runs until 3 October 2024.
See All News